CERA

Science and Research

EXONATE: A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of EXN407 in subjects with Centre Involved Diabetic Macular Oedema secondary to Diabetes Mellitus

This study evaluates the safety and tolerability of EXN407.

Overview

This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved Diabetic Macular Oedema (DMO), with Centre-subfield macular thickness (CMT) between 280-420 µm and Best corrected visual acuity (BCVA) better than or equal to 69 ETDRS score (approximate Snellen equivalent 20/40 (6/12 letters) in the study eye, which is considered secondary to diabetes mellitus.

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.